What question did this study set out to answer?

The aim is to understand how glucocorticoids cause muscle weakness in ECOPD and explore potential treatments.

January 23, 2026

Glucocorticoid-induced muscle weakness in ECOPD: a perspective on mechanisms and emerging pharmacological interventions

Key Points

The aim is to understand how glucocorticoids cause muscle weakness in ECOPD and explore potential treatments.
Focus on glucocorticoid effects on muscle function
Investigate pharmacological interventions
Assess myostatin pathway inhibitors and androgen receptor modulators
Highlight IGF-1-related protein synthesis in muscle recovery
Recognized glucocorticoid-induced muscle weakness as a modifiable issue
Identified promising pharmacological agents for treatment
Effects include increased muscle mass, improved recovery, and reduced hospital stays

Abstract

GC-induced muscle weakness is an under-recognized but potentially modifiable contributor to muscle weakness in ECOPD. Particular promise lies in pharmacological interventions such as myostatin pathway inhibitors, selective androgen receptor modulators, and those inducing IGF-1-related protein synthesis. Dedicated translational and clinical research is urgently needed to evaluate these novel interventions in the setting of ECOPD. Effective countermeasures could preserve muscle mass and function, improve exercise capacity and recovery, shorten hospital stay, and lower the risk of recurrence, offering a new therapeutic opportunity in ECOPD management.

AI से पूछें

Bookmark